LEADER 05394nam 2200661Ia 450 001 9910809106203321 005 20230120004636.0 010 $a1281020451 010 $a9786611020453 010 $a0080521851 035 $a(CKB)1000000000364051 035 $a(EBL)298272 035 $a(OCoLC)476073182 035 $a(SSID)ssj0000117307 035 $a(PQKBManifestationID)11146009 035 $a(PQKBTitleCode)TC0000117307 035 $a(PQKBWorkID)10043400 035 $a(PQKB)11783267 035 $a(MiAaPQ)EBC298272 035 $a(Au-PeEL)EBL298272 035 $a(CaPaEBR)ebr10175706 035 $a(CaONFJC)MIL102045 035 $a(EXLCZ)991000000000364051 100 $a20070420d2007 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCancer immunotherapy $eimmune suppression and tumor growth /$f[edited by] George Prendergast, Elizabeth M. Jaffee 210 $aAmsterdam ;$aBoston $cAcademic Press$dc2007 215 $a1 online resource (429 p.) 300 $aDescription based upon print version of record. 311 0 $a0123725518 320 $aIncludes bibliographical references and index. 327 $aFront cover; Cancer Immunotherapy: Immune Suppression and Tumor Growth; Copyright page; Table of contents; Contributors; PART I: PRINCIPLES OF CANCER IMMUNOBIOLOGY; CHAPTER 1: Introduction; I. OVERVIEW; II. HISTORICAL BACKGROUND; III. LOOKING AHEAD: MARRYING CHEMOTHERAPY AND IMMUNOTHERAPY; IV. PARTS OF THE BOOK; References; Further Reading; CHAPTER 2: Cancer Immunoediting: From Immune Surveillance to Immune Escape; I. INTRODUCTION; II. CANCER IMMUNE SURVEILLANCE; III. CANCER IMMUNOEDITING; IV. CONCLUDING REMARKS; References 327 $aCHAPTER 3: Immunosurveillance: Innate and Adaptive Antitumor ImmunityI. INTRODUCTION; II. INNATE ANTITUMOR RESPONSES; III. INNATE IMMUNE CELLS; IV. ADAPTIVE ANTITUMOR RESPONSES; V. THE INTERPLAY OF INNATE AND ADAPTIVE ANTITUMOR IMMUNITY; VI. CONCLUSION; References; CHAPTER 4: Cytokine Regulation of Immune Tolerance to Tumors; I. INTRODUCTION; II. CYTOKINE REGULATION OF IMMUNE TOLERANCE TO TUMORS; III. SUMMARY AND FUTURE PERSPECTIVES; References; CHAPTER 5: Immunological Sculpting:Natural Killer Cell Receptorsand Ligands; I. INTRODUCTION; II. ACTIVATING HUMAN NK RECEPTORS 327 $aIII. INHIBITORY NK RECEPTORSIV. THE LY49 RECEPTOR FAMILY; V. IMMUNOTHERAPY APPROACHES; VI. CONCLUSION; References; Further Reading; CHAPTER 6: Immune Escape:Immunosuppressive Networks; I. INTRODUCTION; II. IMBALANCE BETWEEN MATURE DCs AND IMMATURE DCs; III. IMBALANCE BETWEEN STIMULATORY AND INHIBITORY B7 FAMILY MOLECULES; IV. IMBALANCE BETWEEN REGULATORY T CELLS AND CONVENTIONAL T CELLS; V. CONCLUDING REMARKS; References; PART II: CANCER THERAPEUTICS; CHAPTER 7: Cytotoxic Chemotherapy inClinical Treatment of Cancer; I. INTRODUCTION; II. DNA-DAMAGING AGENTS; III. ANTIMETABOLITES 327 $aIV. ANTIMITOTICS V. CHEMOTHERAPY REGIMENS; References; Useful Web Sites; CHAPTER 8: Targeted Therapeutics in Cancer Treatment; I. INTRODUCTION; II. CELL CYCLE; III. THE MAPK FAMILY; IV. CHALLENGES IN THE CLINICAL DEVELOPMENT OF SIGNAL TRANSDUCTION INHIBITORS; References; CHAPTER 9: Concepts in Pharmacology and Toxicology; I. INTRODUCTION; II. CONCEPTS IN PHARMACOKINETICS; III. CONCEPTS IN TOXICOLOGY; IV. CLINICAL CONCERNS FOR PHARMACOLOGY AND SAFETY; V. CONCLUSION; References; Further Reading; CHAPTER 10: Cancer Immunotherapy:Challenges and Opportunities; I. INTRODUCTION 327 $aII. PREREQUISITES FOR EFFECTIVE CANCER IMMUNOTHERAPY: IDENTIFYING TUMOR ANTIGENS III. ADOPTIVE ("PASSIVE") IMMUNOTHERAPY; IV. ACTIVE-SPECIFIC IMMUNOTHERAPY: VACCINES; V. CANCER-INDUCED IMMUNOSUPPRESSION IMPINGES ON IMMUNOTHERAPY; VI. CANCER IMMUNOTHERAPY IN MICE VERSUS HUMANS; VII. IMMUNOTHERAPY AND CANCER STEM CELLS; VIII. AUTOIMMUNITY RESULTING FROM CANCER IMMUNOTHERAPY; IX. CONCLUSION AND FUTURE CONSIDERATIONS; References; CHAPTER 11: Cancer Vaccines; I. INTRODUCTION; II. TUMOR ANTIGENS; III. SPONTANEOUS IMMUNITY TO CANCER; IV. TOLERAGENIC PRESSURE ON IMMUNITY TO CANCER 327 $aV. IMMUNE RESPONSES TO CONVENTIONAL VACCINES 330 $aThere has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drug 606 $aCancer$xImmunotherapy 606 $aAntineoplastic agents$xTherapeutic use 606 $aTumors$xImmunological aspects 615 0$aCancer$xImmunotherapy. 615 0$aAntineoplastic agents$xTherapeutic use. 615 0$aTumors$xImmunological aspects. 676 $a616.99/4061 701 $aPrendergast$b George C$01655199 701 $aJaffee$b Elizabeth M$01655200 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910809106203321 996 $aCancer immunotherapy$94007476 997 $aUNINA